Influence of FOLFIRINOX on the achievement of resistability in patients with rectal and liver metastases


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background. According to a number of recent publications, the median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) reaches 30 months. Despite the fact that in the treatment of the third most prevalent disease, 3 main drugs with different mechanisms of action are used: fluorouracil, irinotecan and oxaliplatin, there is still no convincing data on the relationship of 3-component chemotherapy and the sequence of the volume of surgical intervention. Objective. Analysis of the frequency of surgical intervention after the neoadjuvant FOLFIRINOX chemotherapy with an assessment of progression-free survival from the time of treatment and surgical intervention. Methods. Twenty-two patients (8 women, 14 men) with initially diagnosed mCRC, previously not treated, underwent chemotherapeutic treatment with the neoadjuvant regimen FOLFIRINOX ± bevacizumab/cetuximab. The average age was 58 years (up to 50 years -6 patients; over 50 years - 16); the functional status of all patients according ECOG was 0-1. In 11 patients primary tumor was localized in the rectum, in 11 - in the colon (in 5 right-sided lesion, in 6 left-sided lesion). All patients had stage IV disease. Of these, T-Tx - in 3, T1-3 - in 9, T4 - in 10; N-Nx - in 7, N0 - in 3, N+ - in 13 patients. Metastatic lesion was represented mainly by liver metastases -22 patients (12 of them had isolated liver metastases). In addition to the liver, the following organs of 11 patients were involved: umbilicus -1 patient, ovaries - 5, bones - 3, lungs - 2 patients. Results. In the majority of patients (6 patients), neoadjuvant FOLFIRINOX chemotherapy allowed performing simultaneous surgery for both the primary focus and liver metastasis. Conclusion. The use of FOLFIRINOX in a series of observations should be of particular interest in the neoadjuvant treatment strategy for initially inoperable patients, determining the response rate of the primary tumor or secondary manifestations of the disease and the prognosis of the disease. Further studies on the effects of combination therapy and surgical treatment of patients with CRC and liver metastases are warranted.

Texto integral

Acesso é fechado

Sobre autores

G. Khakimov

Tashkent Pediatric Medical Institute, Course of Oncology and Pediatric Oncology; Tashkent City Branch of the Republican Specialized Scientific and Practical Center of Oncology and Radiology

Email: hgg_doc@mail.ru
Postgraduate Student at the Department of Chemotherapy and Combined Treatment of Malignant Tumors

Kh. Dzhumaniezov

Tashkent Pediatric Medical Institute, Course of Oncology and Pediatric Oncology; Tashkent City Branch of the Republican Specialized Scientific and Practical Center of Oncology and Radiology

Sh. Kadyrov

Tashkent Pediatric Medical Institute, Course of Oncology and Pediatric Oncology; Tashkent City Branch of the Republican Specialized Scientific and Practical Center of Oncology and Radiology

G. Khakimova

N.N. Blokhin National Medical Research Center for Oncology

Moscow, Russia

S. Abdulkhuseynova

N.N. Blokhin National Medical Research Center for Oncology

Moscow, Russia

I. Poluzhkina

N.N. Blokhin National Medical Research Center for Oncology

Moscow, Russia

Bibliografia

  1. Parkin D.M., Bray F., Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
  2. Беляева А.В. Мутации в гене K-ras у больных колоректальным раком: эпидемиология и клиническое значение. Дисс. канд. мед. наук. СПб., 2012.
  3. Andre T, Boni C., Mounedji-Boudiaf L., etal. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancel. N Engl J Med. 2004;350:2343-51. doi: 10.1056/NEJMoa032709.
  4. Gill S., Goldberg R.M. First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs. 2004;64:27-44.
  5. Hurwitz H, Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. Doi: 10.1056/ NEJMoa032691.
  6. Cunningham D., Humblet Y, Siena S., et al. Cetuximab monotherapy and cetuximab plus irino- tecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. Doi: 10.1056/ NEJMoa033025.
  7. Adam R. Chemotherapy and surgery: new perspectives on the treat- ment of unresectable liver metastases. Ann Oncol. 2003;14(Suppl. 2):13-6. Doi: 10.1093/ annonc/mdg731.
  8. Varol U, Cirak Y, Cakar B., et al. Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease. J B.U.ON: official journal of the Balkan Union of Oncology. 2013;18:647-52.
  9. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil- leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-14. Doi: 10.1200/ JCO.2004.11.037.
  10. De Gramont A., Figer A., Seymour M., et al. leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47.
  11. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30. doi: 10.1200/JCO.2004.09.046.
  12. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first- line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-76. Doi: 10.1200/ JCO.2006.09.0928.
  13. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Metaanalysis Group In Cancer. J Clin Oncol. 1998;16:301-8. Doi: 10.1200/ JCO.1998.16.1.301.
  14. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer MetaAnalysis Project. J Clin Oncol. 1992;10:896-903. doi: 10.1200/JCO.1992.10.6.896.
  15. Piedbois P, Michiels S. Meta-Analysis Group in Cancer. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated metaanalysis based on 2,751 patients. Proc Am Soc Clin Oncol. 2003;22:294.
  16. Kohne C.H., Van Cutsem E., Wils J.A., et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol. 2003;22:254.
  17. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-47. Doi: 10.1200/ JCO.2000.18.1.136.
  18. Grothey A., Deschler B., Kroening H., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2002;21:129a.
  19. Tournigand C., Andre T., Achille E., et al. FOLFIRI Followed by FOL- FOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol. 2004;22:229-37.
  20. Buyse M., Thirion P, Carlson R.W., et al. Relation between tumor response to first-line chemo- therapy and survival in advanced colorectal cancer: A metaanalysis. Lancet. 2000;356:373-8. DOI: 10.1016/ S0140-6736(00)02528-9.
  21. Giacchetti S., Itzhaki M., Gruia G., et al. Long- term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxali- platin and surgery. Ann Oncol. 1999;10:663-69. doi: 10.1023/a:1008347829017.
  22. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347-53. doi: 10.1007/s10434-001-0347-3.
  23. Bismuth H., Adam R., Levi F, et al. Resection of nonresectable liver metastas.s from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-20.
  24. Folprecht G., Grothey A., Alberts S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311-19. doi: 10.1093/annonc/mdi246.
  25. Alberts S.R., Donohue J.H., Mahoney M.R., et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol. 2003;22:263.
  26. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-39. doi: 10.1093/annonc/mdh217.
  27. de la Camara J., Rodriguez J., Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3593).
  28. Quenet F, Nordlinger B., Rivoire M., et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3613).
  29. Roth A.D., Seium Y, Ruhstaller T., et al. Oxaliplatine (OXA) combined with irinotecan (CPT-11) and 5FU/ leucovorin (OCFL) in metastatic colorectal cancer (MCRC): a phase I-II study. Proc Am Soc Clin Oncol. 2002;21:143a.
  30. Scheele J., Stang R., Altendorf Hofmann A., Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71. doi: 10.1007/bf00316981.
  31. Fong Y, Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-18. doi: 10.1097/00000658-199909000-00004.
  32. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-62.
  33. Figueras J., Valls C., Rafecas A., et al. Resection rate and effect of post- operative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88:980-85. doi: 10.1046/j.0007-1323.2001.01821.x.
  34. Tabernero J., Van Cutsem E., Sastre J., et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/ folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol. 2004;23 (Abstr. 3512).
  35. Folprecht G, Lutz M., Schoffski P, et al. Cetuximab/ irinotecan/ high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Proc Gastrointest Canc Symp. (ASCO/AGA/ASTRO/SSO) 2004;1:(Abstr. 283).
  36. Saltz L.B., Meropol N.J., Loehrer PJ.Sr., et al. Phase H trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-208. doi: 10.1200/JCO.2004.10.182.
  37. Lenz H.-J, Mayer R.J., Gold PJ., et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3510).
  38. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol. 2001;20:3a.
  39. Rougier P, Raoul J.L., Van Laethem J.L., et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3513).
  40. Lutz M.P, Schoffski P, Folprecht G., et al. A phase I/ II study of cetuximab (C225) plus irinotecan (CPT-11) and 24 h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol. 2002;13:73.
  41. Rosenberg A.H., Loehrer P.J., Needle M., et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am SocClin Oncol. 2002;21:135a.
  42. Scappaticci F., Fehrenbacher L., Cartwright T., et al. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab. Proc Gastrointest Canc Symp. (ASCO/ AGA/ASTRO/SSO) 2004;1:(Abstr. 235).
  43. Chaix M., Vincent J., Lorgis V., Ghiringhelli F. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. Oncol. 2014;87:148-58. doi: 10.1159/000361031.
  44. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases. Ann. Surg. 2004;240:1052-61. doi: 10.1097/01. sla.0000145964.08365.01.
  45. Sanoff H., Sargent D., Campbell M., et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N 9741. JClin Oncol. 2008;26:5721-27. doi: 10.1200/JCO.2008.17.7147.
  46. Choti M.A. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-66. doi: 10.1097/00000658-200206000-00002.
  47. Nordlinger B., Sorbye H., Glimelius B., et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol. 2012;30(Abstr. 3508).
  48. Adam R., Frilling A., Elias D., et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010;97:366-76. doi: 10.1002/bjs.6889.
  49. Abdalla E.K., Vauthey J.N. Colorectal metastases: resect or ablate? Ann Surg Oncol. 2006;13:602-3. doi: 10.1245/ASO.2006.09.920.
  50. Ferrero A. Postoperative liver dysfunction and future remnant liver: Where is the limit? Results of a prospective study. World J Surg. 2007;31:1643-51. doi: 10.1007/s00268-007-9123-2.
  51. Oki E., Emi Y, Yamanaka T, et al. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). Br J Cancer 2019. doi: 10.1038/s41416-019-0518-2.
  52. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008. 26:1830-35. doi: 10.1200/JCO.2007.13.7679.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies